Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.58 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205150 | 1.00 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL118591 | 0.88 | NFE2L2 (0.79) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL7870072 | 0.82 | NFE2L2 (0.66) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL615385 | 0.82 | NFE2L2 (0.77) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL14518616 | 0.82 | NFE2L2 (0.66) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL21798669 | 0.82 | NFE2L2 (0.66) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL5182341 | 0.81 | NFE2L2 (0.69) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL1045609 | 0.81 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL1045608 | 0.81 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL26603685 | 0.80 | NFE2L2 (0.58) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304324-B1 | SEROTONIN REUPTAKE INHIBITORS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-6787560-B2 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030191126-A1 | Psychological disorders; antidepressants | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-10-09 | — | — | US | disclosed |
| EP-1304324-A1 | SEROTONIN REUPTAKE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191126-A1 | Psychological disorders; antidepressants | CRH, HTR2C, HTR1A | NFE2L2 1851/4885CYP1A1 494/4885CYP1A2 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.